Cantor Fitzgerald Maintains Overweight on LifeMD, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on LifeMD (NASDAQ:LFMD) and raises the price target from $7 to $8.
October 02, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD's price target has been raised from $7 to $8 by Cantor Fitzgerald, maintaining an Overweight rating.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100